CA3174498A1 - Reducing or inhibiting ocular damage by hyaluronidase administration - Google Patents

Reducing or inhibiting ocular damage by hyaluronidase administration Download PDF

Info

Publication number
CA3174498A1
CA3174498A1 CA3174498A CA3174498A CA3174498A1 CA 3174498 A1 CA3174498 A1 CA 3174498A1 CA 3174498 A CA3174498 A CA 3174498A CA 3174498 A CA3174498 A CA 3174498A CA 3174498 A1 CA3174498 A1 CA 3174498A1
Authority
CA
Canada
Prior art keywords
minutes
hyaluronidase
composition
eye
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174498A
Other languages
English (en)
French (fr)
Inventor
Steve YOELIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med Progress LLC
Original Assignee
Med Progress LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Progress LLC filed Critical Med Progress LLC
Publication of CA3174498A1 publication Critical patent/CA3174498A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
CA3174498A 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration Pending CA3174498A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
US63/004,444 2020-04-02
PCT/US2021/025668 WO2021203062A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Publications (1)

Publication Number Publication Date
CA3174498A1 true CA3174498A1 (en) 2021-10-07

Family

ID=77921064

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174498A Pending CA3174498A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Country Status (11)

Country Link
US (1) US11878051B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125928A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521059A (cg-RX-API-DMAC7.html)
KR (1) KR20230005198A (cg-RX-API-DMAC7.html)
CN (1) CN115697348A (cg-RX-API-DMAC7.html)
AU (1) AU2021248653B2 (cg-RX-API-DMAC7.html)
CA (1) CA3174498A1 (cg-RX-API-DMAC7.html)
IL (1) IL296979A (cg-RX-API-DMAC7.html)
MX (1) MX2022012426A (cg-RX-API-DMAC7.html)
WO (1) WO2021203062A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003755A (es) * 2021-09-25 2024-04-15 Med Progress Llc Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa.
KR102922198B1 (ko) * 2022-04-25 2026-02-03 주식회사 메디팹 조직 수복용 생체재료의 분해 또는 교정용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
KR100566451B1 (ko) * 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Also Published As

Publication number Publication date
ZA202211833B (en) 2023-04-26
WO2021203062A1 (en) 2021-10-07
JP2026065067A (ja) 2026-04-14
AU2021248653B2 (en) 2024-05-02
MX2022012426A (es) 2023-01-11
CN115697348A (zh) 2023-02-03
EP4125928A1 (en) 2023-02-08
US20210308234A1 (en) 2021-10-07
IL296979A (en) 2022-12-01
US11878051B2 (en) 2024-01-23
EP4125928A4 (en) 2024-06-12
JP2023521059A (ja) 2023-05-23
AU2021248653A1 (en) 2022-12-01
KR20230005198A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
JP2026065067A (ja) ヒアルロニダーゼの投与による目の損傷の低減又は抑制
Blumenkranz et al. Fluid-gas exchange and photocoagulation after vitrectomy: indications, technique, and results
Kushner et al. Medical treatment of glaucoma associated with cicatricial retinopathy of prematurity
CN101107006A (zh) 治疗黏连性关节囊炎的方法
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
Ramon et al. Retinal toxicity of intravitreal injection of ziv-aflibercept in albino rabbits
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
CRAIG BROWN et al. Use of dilute drug solutions for routine cycloplegia and mydriasis
US20250134966A1 (en) Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration
US20220331157A1 (en) Thermoresponsive polymers and uses thereof
Alfayyadh et al. Advanced eales’ disease with neovascular glaucoma at first presentation
US20060034890A1 (en) Device for ocular delivery of active principles by the transpalpebral route
Yeniad et al. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases
Loy et al. Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines
Stubbs et al. Penetrating eye injury from a rigid infant pacifier
RU2104679C1 (ru) Офтальмологическое лекарственное средство
KR102879076B1 (ko) Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
Bada et al. Proptosis in a Nigerian indigenous bitch.
SU1683740A1 (ru) Способ введени лекарственных веществ дл лечени заболеваний глаз
KR20100109549A (ko) Tgf-베타 3을 사용한 흉터의 억제
Mazza et al. Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits
Bolaji-Alabi et al. CONSERVATIVE SURGICAL MANAGEMENT OF UNILATERAL TRAUMATIC PROPTOSIS IN AN EIGHT WEEK OLD BOERBOEL
Soekamto et al. Intravitreal Injections for Pediatric Retinal Diseases
Cimberle et al. FEMCAT study evaluates value of femtosecond cataract surgery.
Hushaw Air Travel & IOLs

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241028

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250320

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250320

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250513

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250516

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250521

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260331

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260623